During an inspection from July 30 to Sept. 24, 2024, at Hologic’s Marlborough, Massachusetts, facility, the FDA identified several deficiencies related to the production of BioZorb, a class II ...
Hologic received a warning letter in December from the Food and Drug Administration related to safety concerns with the company’s Biozorb implantable radiographic markers. The FDA found that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results